Product NDC: | 0173-0434 |
Proprietary Name: | FORTAZ |
Non Proprietary Name: | ceftazidime |
Active Ingredient(s): | 20 mg/mL & nbsp; ceftazidime |
Administration Route(s): | INTRAMUSCULAR; INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0173-0434 |
Labeler Name: | GlaxoSmithKline LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA050578 |
Marketing Category: | NDA |
Start Marketing Date: | 19920826 |
Package NDC: | 0173-0434-00 |
Package Description: | 25 VIAL in 1 TRAY (0173-0434-00) > 18 mL in 1 VIAL |
NDC Code | 0173-0434-00 |
Proprietary Name | FORTAZ |
Package Description | 25 VIAL in 1 TRAY (0173-0434-00) > 18 mL in 1 VIAL |
Product NDC | 0173-0434 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | ceftazidime |
Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
Route Name | INTRAMUSCULAR; INTRAVENOUS |
Start Marketing Date | 19920826 |
Marketing Category Name | NDA |
Labeler Name | GlaxoSmithKline LLC |
Substance Name | CEFTAZIDIME SODIUM |
Strength Number | 20 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Cephalosporin Antibacterial [EPC],Cephalosporins [Chemical/Ingredient] |